Treatment of Haemophilus influenzae Infections

First-Line Treatment Options

The American Academy of Otolaryngology-Head and Neck Surgery recommends amoxicillin-clavulanate as the preferred oral treatment for non-severe H. influenzae infections, particularly for lower respiratory tract infections, otitis media, and sinusitis 1
The preferred ratio of amoxicillin to clavulanate is 14:1 to minimize gastrointestinal side effects while maintaining efficacy 1
According to antimicrobial activity data, gatifloxacin, moxifloxacin, ceftriaxone, cefixime, cefpodoxime proxetil, and extended-release amoxicillin-clavulanate are 95-100% effective against H. influenzae 2

For bronchitis or non-severe pneumonia where H. influenzae is suspected, the first choice is oral co-amoxiclav (amoxicillin-clavulanate) or a tetracycline such as doxycycline, with alternative options including macrolides (clarithromycin preferred over erythromycin) or respiratory fluoroquinolones (levofloxacin or moxifloxacin) 3, 4, 5
For severe pneumonia or systemic infections, the first choice is parenteral therapy with ceftriaxone or cefotaxime, with an alternative regimen of intravenous co-amoxiclav 4

Between 18-42% of H. influenzae isolates produce β-lactamase, making plain amoxicillin or ampicillin ineffective in these cases, and β-lactamase-stable antibiotics should always be used in areas with high rates of β-lactamase-producing H. influenzae 1, 5
Treatment duration is typically 7 days for non-severe infections, and 10-14 days for severe infections 3, 4

If no improvement after 48-72 hours of initial therapy, consider switching to a broader-spectrum agent like ceftriaxone, checking for antimicrobial resistance patterns in your region, or reevaluating the diagnosis and considering additional pathogens 1, 5, 4

Levofloxacin resistance in H. influenzae has increased significantly in some regions, and regular monitoring of local resistance patterns is essential for guiding empiric therapy 5, 1

The American Thoracic Society recommends that for outpatients with community-acquired pneumonia and cardiopulmonary disease or modifying factors, a β-lactam plus macrolide combination or antipneumococcal fluoroquinolone monotherapy should be used 6, 7
H. influenzae is particularly common in cigarette smokers with community-acquired pneumonia, according to the American Journal of Respiratory and Critical Care Medicine 6, 7